<DOC>
	<DOCNO>NCT01815411</DOCNO>
	<brief_summary>Rheumatoid Arthritis ( RA ) chronic , autoimmune inflammatory disease lead significant pain , joint destruction functional decline , substantial economic impact sufferer society . Although etiology RA unknown , generally accept arises interplay genetic predisposition ( particular , HLA-DR allele subtypes specific gene polymorphism ) , immunological deregulation ( e. g. autoantibody production ) , environmental factor . The prevalence incidence RA Norway estimate 0,4-0,5 % 0,020-0,025 % , respectively , incidence rate 2-4-fold high woman . Synovitis bone resorption key pathogenetic factor RA patient elevate cytokine level joint blood ( i.e . TNF , IL-1 , IL-6 ) . RA also associate significant comorbidity ; important premature cardiovascular disease significantly contribute increased mortality . Compared general population , mortality RA 1,57-2,0-fold high Norway Sweden , mean life expectancy reduce average 5-10 year . Medical treatment RA consist nonsteroidal anti-inflammatory drug , systemic glucocorticosteroids , traditional disease modify antirheumatic drug ( include methotrexate ) biologic therapy ( include anti-tumor necrosis factor ( TNF ) α , anti-IL 6 anti-CD20 therapy ) . Also , considerable portion patient need joint replacement surgery need rehabilitation . However , treatment opportunity still optimal . In large proportion patient , full control disease possible due limited effect available therapy and/or intolerance therapy . Therefore , huge need find new therapeutic alternative treat RA . Since study healthy volunteer IBD-patients support mushroom extract AndoSanTM exert anti-inflammatory effect vivo , investigator want examine pilot study whether effect also evident patient RA . A potential anti-inflammatory effect could prove beneficial seriously ill patient , accordingly could experience less side effect ( edema , granulocytopenia , diminish tissue repair ) due potential reduction number dose disease modify drug .</brief_summary>
	<brief_title>Effect Andosan Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Main aim : Examine whether daily oral ingestion immunomodulatory mushroom extract ( AndoSanTM ) lead clinical , biochemical genetical improvement RA . The experiment carry 21 day 15 eligible RA patient . In order increase scientific value project use , far possible , age match control group RA patient steady medication intervention . The control group 10-15 patient answer questionnaire give sample blood feces . Partial aim : To compare prior ( day 0 ) ( day 21 ) daily ( 30 ml x 2 ) ingestion Andosan effect therapy : - general blood sample ( leucocyte , CRP , liver renal function test ) , include erythrocyte sedimentation rate ( SR ) pentraxin 3 ( PTX3 ) - level blood cytokine analytes ( IL-1α/-1ra/-2/-4/-5/-6/-7/-8/-9/-10/-12 ( p70 ) /-13/-15/ 17 , G-CSF , GM-CSF , MCP-1 , MIP-1ß/-1α , IFNγ , TNFα basic FGF , eotaxin , PDGF-BB , RANTES , VEGF ; 27-plex ) -level inflammatory marker calprotectin feces blood patient - genetic expression blood leukocyte ( microarray ) -number swell tender joint , morning stiffness , Disease activity score 28 calculated ESR ( DAS28-ESR ) , RA impact disease score ( RAID ) , Health Assessment Questionnaire ( HAQ ) , visual analogue scale ( VAS ) patient 's physician 's global assessment disease activity , life quality ( SF-36 version 2 ) , fatigue score . Partial aim : To compare prior ( day 0 ) ( day 21 ) daily ( 30 ml x 2 ) ingestion Andosan effect therapy : - general blood sample ( leucocyte , CRP , liver renal function test ) , include erythrocyte sedimentation rate ( SR ) pentraxin 3 ( PTX3 ) - level blood cytokine analytes ( IL-1α/-1ra/-2/-4/-5/-6/-7/-8/-9/-10/-12 ( p70 ) /-13/-15/ 17 , G-CSF , GM-CSF , MCP-1 , MIP-1ß/-1α , IFNγ , TNFα basic FGF , eotaxin , PDGF-BB , RANTES , VEGF ; 27-plex ) -level inflammatory marker calprotectin feces blood patient - genetic expression blood leukocyte ( microarray ) -number swell tender joint , morning stiffness , Disease activity score 28 calculated ESR ( DAS28-ESR ) , RA impact disease score ( RAID ) , Health Assessment Questionnaire ( HAQ ) , visual analogue scale ( VAS ) patient 's physician 's global assessment disease activity , life quality ( SF-36 version 2 ) , fatigue score .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Age &gt; 18 year Able willing give write informed consent , comply requirement study protocol . Fulfilling ACR 1987 revise diagnostic criterion diagnosis rheumatoid arthritis . Moderate disease activity base clinical evaluation include DAS28ESR ( DAS28 3.25.1 ) [ 11 , 12 ] . Stable medication disease modify drug ( DMARDs ) systemic glucocorticosteroids 3 month prior inclusion . Lack cooperativity . Clinically significant chronic infection , include positive serology hepatitis B C , history positive HIV status . Acute significant infection last 3 week inclusion . Surgery last 4 week inclusion , study period . Clinically significant malignancy . Drug addiction Any inflammatory disease permanence relate RA . Use prednisolone &gt; 7,5 mg daily 1 month prior inclusion . Use biologic treatment include antibody cytokine receptor 6 week prior inclusion . Use intramuscular , intraarticular intravenous injection corticosteroid within 4 week prior inclusion trial . Vaccination trial . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>symptom score</keyword>
	<keyword>fatigue</keyword>
	<keyword>life quality</keyword>
	<keyword>cytokine</keyword>
	<keyword>mRNA expression</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Signs Symptoms</keyword>
	<keyword>Indication Modification Patient Physical Status</keyword>
</DOC>